Is CagriSema FDA Approved?

DrugStatusIndex provides a clear, data-driven view of the regulatory status of medications, compounds, and related products. This page explains whether CagriSema is FDA approved and how it is commonly categorized.

▤

Overview

CagriSema is an investigational once-weekly injectable combination of cagrilintide and semaglutide being developed by Novo Nordisk for obesity and weight management treatment.

FDA Status Details

CagriSema is classified as Not FDA Approved. Novo Nordisk submitted a New Drug Application (NDA) to the FDA in December 2025, but as of 2026 it remains under FDA review and is not yet approved for prescription use. :contentReference[oaicite:0]{index=0}

Clinical Trial Progress

Phase 3 REDEFINE trials showed significant weight loss results, including approximately 23% average body weight reduction in certain study groups. Additional higher-dose studies are planned through 2026. :contentReference[oaicite:1]{index=1}

⚗

Availability Status

Because CagriSema is still under regulatory review, it is not currently available as an FDA-approved prescription medication in the United States. Any current access claims should be treated carefully.

CagriSema FDA Status

Not FDA Approved

CagriSema is listed as Not FDA Approved. It is currently under FDA review following Novo Nordisk’s NDA submission and is not yet an approved prescription medication. :contentReference[oaicite:2]{index=2}

Why People Search This

Users often search for CagriSema to understand whether it is already available for weight loss, how it compares to Wegovy or Zepbound, and when FDA approval may happen.

Disclaimer

This page is for informational purposes only and reflects publicly available regulatory data. It does not provide medical advice or treatment recommendations.

Search Another Drug or Compound

Use DrugStatusIndex to review public regulatory status information for medications, compounds, and related products.

Search the Index